<h2 data-section-id="1hr0ifi" data-start="0" data-end="38"><strong>Non-Small Cell Lung Cancer Market</strong></h2>
<h2 data-section-id="1n0b2de" data-start="40" data-end="58"><strong>Market Overview</strong></h2>
<p data-start="59" data-end="339"><a href="https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-market"><strong>Non-Small Cell Lung Cancer (NSCLC)</strong></a> is the most common type of lung cancer, accounting for nearly 81% of all lung cancer diagnoses. Early diagnosis offers the best prognosis; however, most patients are diagnosed at advanced stages due to nonspecific symptoms and delayed detection.</p>
<h2 data-section-id="10ousyj" data-start="341" data-end="370"><strong>Current Treatment Options</strong></h2>
<ul data-start="371" data-end="450">
<li data-section-id="36j8tj" data-start="371" data-end="385">Chemotherapy</li>
<li data-section-id="1c0g5ff" data-start="386" data-end="404">Targeted Therapy</li>
<li style="font-weight: bold;" data-section-id="y0me1i" data-start="405" data-end="420"><a href="https://www.delveinsight.com/report-store/immunotherapy-drugs-market"><strong>Immunotherapy</strong></a></li>
<li data-section-id="1ldrzed" data-start="421" data-end="430">Surgery</li>
<li data-section-id="xnxfs8" data-start="431" data-end="450">Radiation Therapy</li>
</ul>
<h2 data-section-id="1lif148" data-start="452" data-end="483"><strong>Current Treatment Landscape</strong></h2>
<ul data-start="484" data-end="727">
<li data-section-id="s8xqd2" data-start="484" data-end="598"><a href="https://www.delveinsight.com/report-store/egfr-market-forecast"><strong>EGFR</strong></a> exon 20 insertion mutations have emerged as one of the most competitive areas in NSCLC therapy development.</li>
<li data-section-id="y0n57d" data-start="599" data-end="727">Uncommon EGFR mutations such as:
<ul data-start="636" data-end="727">
<li data-section-id="171qutk" data-start="636" data-end="643">G719X</li>
<li data-section-id="179q3aj" data-start="646" data-end="653">S768I</li>
<li data-section-id="n911ru" data-start="656" data-end="727">PACC mutations<br data-start="672" data-end="675">are becoming important future therapeutic targets.</li>
</ul>
</li>
</ul>
<h2 data-section-id="8ysjlg" data-start="729" data-end="761"><strong>ALK-positive NSCLC Landscape</strong></h2>
<ul data-start="762" data-end="959">
<li data-section-id="1su6m1z" data-start="762" data-end="824">ALECENSA and ALUNBRIG are the preferred first-line ALK TKIs.</li>
<li data-section-id="5crrqt" data-start="825" data-end="881">ALECENSA currently dominates the ALK treatment market.</li>
<li data-section-id="1mq5vkd" data-start="882" data-end="959">Prior to these therapies, XALKORI was the standard frontline ALK treatment.</li>
</ul>
<h2 data-section-id="15c16ne" data-start="961" data-end="993"><strong>KRAS-mutated NSCLC Landscape</strong></h2>
<ul data-start="994" data-end="1237">
<li data-section-id="2ruyy2" data-start="994" data-end="1050">KRAS G12C is the most frequent <a href="https://www.delveinsight.com/report-store/kras-inhibitors-market"><strong>KRAS</strong></a> mutation in NSCLC.</li>
<li data-section-id="gouw0j" data-start="1051" data-end="1119">The G12C segment is becoming increasingly crowded and competitive.</li>
<li data-section-id="1swetiq" data-start="1120" data-end="1237">Future opportunities are expected in:
<ul data-start="1162" data-end="1237">
<li data-section-id="14d2s91" data-start="1162" data-end="1203">Relapsed/Refractory patient populations</li>
<li data-section-id="fq65io" data-start="1206" data-end="1237">First-line treatment settings</li>
</ul>
</li>
</ul>
<h2 data-section-id="kserx0" data-start="1239" data-end="1257"><strong>Market Insights</strong></h2>
<ul data-start="1258" data-end="1784">
<li data-section-id="1j9d479" data-start="1258" data-end="1334">The <strong><a href="https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market">NSCLC Market Size</a></strong> in the 7MM was approximately USD 33 billion in 2025.</li>
<li data-section-id="1jnzx6b" data-start="1335" data-end="1404">The market is projected to grow at a CAGR of 6.6% during 2026&ndash;2036.</li>
<li data-section-id="u9rpaq" data-start="1405" data-end="1494">EGFR-mutated NSCLC market size in the US reached approximately USD 3.8 billion in 2025.</li>
<li data-section-id="1jcaqei" data-start="1495" data-end="1583">ALK-mutated NSCLC market size in the US reached approximately USD 1.2 billion in 2025.</li>
<li data-section-id="15o00az" data-start="1584" data-end="1652">EGFR remains one of the most profitable biomarker-driven segments.</li>
<li data-section-id="6ym6y5" data-start="1653" data-end="1719">TAGRISSO is currently the dominant EGFR inhibitor in the market.</li>
<li data-section-id="1yoq154" data-start="1720" data-end="1784">KEYTRUDA generated the highest revenue in the 7MM during 2025.</li>
</ul>
<h2 data-section-id="1bq5gh8" data-start="1786" data-end="1803"><strong>Market Drivers</strong></h2>
<ul data-start="1804" data-end="1913">
<li data-section-id="1vnh61h" data-start="1804" data-end="1828">Rising NSCLC incidence</li>
<li data-section-id="1q0pc2b" data-start="1829" data-end="1879">Growing opportunities in EGFR-targeted therapies</li>
<li data-section-id="rqi6lm" data-start="1880" data-end="1913">Expanding competitive landscape</li>
</ul>
<h2 data-section-id="9gzxq3" data-start="1915" data-end="1929"><strong>Unmet Needs</strong></h2>
<ul data-start="1930" data-end="2087">
<li data-section-id="1k4som5" data-start="1930" data-end="1968">Antibiotic-associated ICI resistance</li>
<li data-section-id="moqes8" data-start="1969" data-end="2005">High cost of combination therapies</li>
<li data-section-id="100o0k5" data-start="2006" data-end="2042">Reimbursement challenges in Europe</li>
<li data-section-id="va42bu" data-start="2043" data-end="2087">Treatment gaps in molecularly driven NSCLC</li>
</ul>
<h2 data-section-id="1n0j3ag" data-start="2089" data-end="2105"><strong>SWOT Analysis</strong></h2>
<h2 data-section-id="1drvzf4" data-start="2107" data-end="2120"><strong>Strengths</strong></h2>
<ul data-start="2121" data-end="2238">
<li data-section-id="yceg1f" data-start="2121" data-end="2238">Availability of chemotherapy combination regimens strengthens therapeutic options and may improve patient outcomes.</li>
</ul>
<h2 data-section-id="h0uowz" data-start="2240" data-end="2254"><strong>Weaknesses</strong></h2>
<ul data-start="2255" data-end="2357">
<li data-section-id="1n0vm8o" data-start="2255" data-end="2357">Most patients eventually develop resistance to EGFR-TKIs despite improved survival and tolerability.</li>
</ul>
<h2 data-section-id="tg2f4p" data-start="2359" data-end="2376"><strong>Opportunities</strong></h2>
<ul data-start="2377" data-end="2481">
<li data-section-id="269m0u" data-start="2377" data-end="2481">Discovery of novel targetable biomarkers creates opportunities for innovative therapeutic development.</li>
</ul>
<h2 data-section-id="12vcqsr" data-start="2483" data-end="2494">Threats</h2>
<ul data-start="2495" data-end="2600">
<li data-section-id="q6tbef" data-start="2495" data-end="2600">Rare biomarkers create challenges for research, clinical development, and patient enrollment in trials.</li>
</ul>
<h2 data-section-id="svqncy" data-start="2607" data-end="2651"><strong>Non-Small Cell Lung Cancer Epidemiology</strong></h2>
<h2 data-section-id="1ceeu4t" data-start="2653" data-end="2677"><strong>Epidemiology Overview</strong></h2>
<p data-start="2678" data-end="2729">Early diagnosis remains critical in NSCLC; however:</p>
<ul data-start="2730" data-end="2915">
<li data-section-id="11r2nzj" data-start="2730" data-end="2823">Symptoms are often mistaken for smoking-related conditions or common respiratory illnesses.</li>
<li data-section-id="f65frh" data-start="2824" data-end="2915">Nearly 80% of patients are diagnosed at advanced stages, making treatment more difficult.</li>
</ul>
<h2 data-section-id="ciy1gw" data-start="2917" data-end="2945"><strong>Epidemiology Segmentation</strong></h2>
<ul data-start="2946" data-end="3145">
<li data-section-id="1y7x4kj" data-start="2946" data-end="2977">Total Incident Cases of NSCLC</li>
<li data-section-id="eyly0t" data-start="2978" data-end="3001">Gender-specific Cases</li>
<li data-section-id="ys6mox" data-start="3002" data-end="3022">Age-specific Cases</li>
<li data-section-id="xb04ae" data-start="3023" data-end="3049">Histology-specific Cases</li>
<li data-section-id="xr6o1y" data-start="3050" data-end="3072">Stage-specific Cases</li>
<li data-section-id="1amx17e" data-start="3073" data-end="3108">Biomarker/Mutation-specific Cases</li>
<li data-section-id="13l9o3a" data-start="3109" data-end="3145">Line-wise Treated Metastatic Cases</li>
</ul>
<h2 data-section-id="1mqvshr" data-start="3147" data-end="3178"><strong>Epidemiology Insights (2025)</strong></h2>
<ul data-start="3179" data-end="3626">
<li data-section-id="rsu77g" data-start="3179" data-end="3218">Total incident cases in the 7MM: 539K</li>
<li data-section-id="ejv5jz" data-start="3219" data-end="3294">Regional distribution:
<ul data-start="3246" data-end="3294">
<li data-section-id="l5mny2" data-start="3246" data-end="3255">US: 38%</li>
<li data-section-id="f97t6d" data-start="3258" data-end="3279">EU4 and the UK: 39%</li>
<li data-section-id="1x5o28y" data-start="3282" data-end="3294">Japan: 23%</li>
</ul>
</li>
<li data-section-id="1sgmqvf" data-start="3295" data-end="3424">Incident cases are expected to rise during 2026&ndash;2036 due to:
<ul data-start="3360" data-end="3424">
<li data-section-id="v9x7gv" data-start="3360" data-end="3387">Increasing disease burden</li>
<li data-section-id="15mcd7r" data-start="3390" data-end="3424">Improved diagnostic capabilities</li>
</ul>
</li>
<li data-section-id="21clj5" data-start="3425" data-end="3475">NSCLC is slightly more common in men than women.</li>
<li data-section-id="vfd5r8" data-start="3476" data-end="3557">Disease prevalence is significantly higher in patients aged 65 years and older.</li>
<li data-section-id="1t5phhi" data-start="3558" data-end="3626">Cases among individuals younger than 65 years are also increasing.</li>
</ul>
<h2 data-section-id="44n60j" data-start="3628" data-end="3663"><strong>Histology Distribution in the US</strong></h2>
<ul data-start="3664" data-end="3761">
<li data-section-id="sjg6rn" data-start="3664" data-end="3685">Adenocarcinoma: 57%</li>
<li data-section-id="56bk1q" data-start="3686" data-end="3716">Squamous cell carcinoma: 28%</li>
<li data-section-id="sxg6sp" data-start="3717" data-end="3743">Large cell carcinoma: 2%</li>
<li data-section-id="1imfzz3" data-start="3744" data-end="3761">Others/NOS: 13%</li>
</ul>
<h2 data-section-id="1qebaqh" data-start="3763" data-end="3789"><strong>Stage-specific Insights</strong></h2>
<ul data-start="3790" data-end="3979">
<li data-section-id="m7em6j" data-start="3790" data-end="3844">Most NSCLC cases are diagnosed at advanced Stage IV.</li>
<li data-section-id="13jx5zk" data-start="3845" data-end="3979">Contributing factors include:
<ul data-start="3879" data-end="3979">
<li data-section-id="lq904f" data-start="3879" data-end="3898">Delayed diagnosis</li>
<li data-section-id="v4evtg" data-start="3901" data-end="3927">Limited screening access</li>
<li data-section-id="1xcrfhx" data-start="3930" data-end="3952">Nonspecific symptoms</li>
<li data-section-id="4yla40" data-start="3955" data-end="3979">Socioeconomic barriers</li>
</ul>
</li>
</ul>
<h2 data-section-id="1ww6qft" data-start="3981" data-end="4000"><strong>Common Symptoms</strong></h2>
<ul data-start="4001" data-end="4225">
<li data-section-id="1eonc5w" data-start="4001" data-end="4032">Persistent or worsening cough</li>
<li data-section-id="1ehieep" data-start="4033" data-end="4052">Coughing up blood</li>
<li data-section-id="1i01w53" data-start="4053" data-end="4065">Chest pain</li>
<li data-section-id="1tct0ab" data-start="4066" data-end="4088">Breathing difficulty</li>
<li data-section-id="th6bbh" data-start="4089" data-end="4099">Wheezing</li>
<li data-section-id="1h4jc9t" data-start="4100" data-end="4112">Hoarseness</li>
<li data-section-id="uyio7e" data-start="4113" data-end="4131">Loss of appetite</li>
<li data-section-id="10ybydy" data-start="4132" data-end="4157">Unexplained weight loss</li>
<li style="font-weight: bold;" data-section-id="19q95z9" data-start="4158" data-end="4167"><a href="https://www.delveinsight.com/report-store/fatigue-pipeline-insight"><strong>Fatigue</strong></a></li>
<li data-section-id="qo7zj6" data-start="4168" data-end="4188">Trouble swallowing</li>
<li data-section-id="8hsfpr" data-start="4189" data-end="4225">Swelling in the face or neck veins</li>
</ul>
<h3 data-section-id="1pndr9h" data-start="4227" data-end="4240"><strong>Diagnosis</strong></h3>
<ul data-start="4241" data-end="4379">
<li data-section-id="v5ul2m" data-start="4241" data-end="4271">Imaging tests (<a href="https://www.delveinsight.com/report-store/magnetic-resonance-imaging-devices-market"><strong>MRI</strong></a>, <a href="https://www.delveinsight.com/report-store/computed-tomography-market"><strong>CT</strong></a>, PET)</li>
<li data-section-id="9pae06" data-start="4272" data-end="4294">Bronchoscopic biopsy</li>
<li data-section-id="ktdh21" data-start="4295" data-end="4325">Immunohistochemical staining</li>
<li data-section-id="4yyqqg" data-start="4326" data-end="4341">Thoracentesis</li>
<li data-section-id="1xjv7v2" data-start="4342" data-end="4359">Sputum cytology</li>
<li data-section-id="ogbg54" data-start="4360" data-end="4379">Biomarker testing</li>
</ul>
<p data-start="4381" data-end="4422"><em data-start="4381" data-end="4422">These figures represent 2025 data only.</em></p>
<h2 data-section-id="rnjvka" data-start="4429" data-end="4469"><strong>Non-Small Cell Lung Cancer Pipeline</strong></h2>
<h2 data-section-id="ipflbs" data-start="4471" data-end="4492"><strong>Emerging Therapies</strong></h2>
<ul data-start="4494" data-end="5295">
<li data-section-id="6jabl4" data-start="4494" data-end="4627"><strong data-start="4496" data-end="4526">BMS-986504 + Pembrolizumab</strong>
<ul data-start="4531" data-end="4627">
<li data-section-id="v65f3a" data-start="4531" data-end="4564">Company: Bristol Myers Squibb</li>
<li data-section-id="hrbciy" data-start="4567" data-end="4585">RoA: Oral + IV</li>
<li data-section-id="2kjj3w" data-start="4588" data-end="4627">MoA: PRMT5 inhibitor + PD-1 inhibitor</li>
</ul>
</li>
<li data-section-id="shtuao" data-start="4629" data-end="4785"><strong data-start="4631" data-end="4669">Iza-bren (izalontamab brengitecan)</strong>
<ul data-start="4674" data-end="4785">
<li data-section-id="5na1nb" data-start="4674" data-end="4722">Company: SystImmune and Bristol Myers Squibb</li>
<li data-section-id="hrbciy" data-start="4725" data-end="4743">RoA: Oral + IV</li>
<li data-section-id="1yjbn03" data-start="4746" data-end="4785">MoA: EGFR &times; HER3 inhibitor + EGFR TKI</li>
</ul>
</li>
<li data-section-id="5oqsap" data-start="4787" data-end="4878"><strong data-start="4789" data-end="4813">Neladalkib (NVL-655)</strong>
<ul data-start="4818" data-end="4878">
<li data-section-id="tg1h0q" data-start="4818" data-end="4839">Company: Nuvalent</li>
<li data-section-id="c0ka3i" data-start="4842" data-end="4855">RoA: Oral</li>
<li data-section-id="1ih44oj" data-start="4858" data-end="4878">MoA: ALK inhibitor</li>
</ul>
</li>
<li data-section-id="13anljq" data-start="4880" data-end="4981"><strong data-start="4882" data-end="4909">PF-08046054 (SGN-PDL1V)</strong>
<ul data-start="4914" data-end="4981">
<li data-section-id="1wadnl3" data-start="4914" data-end="4933">Company: Pfizer</li>
<li data-section-id="1g9ii7y" data-start="4936" data-end="4956">RoA: IV infusion</li>
<li data-section-id="4jtuk1" data-start="4959" data-end="4981">MoA: PD-L1 inhibitor</li>
</ul>
</li>
<li data-section-id="dtp6pv" data-start="4983" data-end="5084"><strong data-start="4985" data-end="4997">FF-10832</strong>
<ul data-start="5002" data-end="5084">
<li data-section-id="1jl5011" data-start="5002" data-end="5035">Company: FUJIFILM Corporation</li>
<li data-section-id="c0ka3i" data-start="5038" data-end="5051">RoA: Oral</li>
<li data-section-id="a9c6x6" data-start="5054" data-end="5084">MoA: DNA synthesis inhibitor</li>
</ul>
</li>
<li data-section-id="1jx6b4g" data-start="5086" data-end="5192"><strong data-start="5088" data-end="5098">BNT116</strong>
<ul data-start="5103" data-end="5192">
<li data-section-id="1cuo22t" data-start="5103" data-end="5153">Company: BioNTech SE/Regeneron Pharmaceuticals</li>
<li data-section-id="1b8gn0x" data-start="5156" data-end="5167">RoA: IV</li>
<li data-section-id="jdp0b1" data-start="5170" data-end="5192">MoA: Immunostimulant</li>
</ul>
</li>
<li data-section-id="wcsmek" data-start="5194" data-end="5295"><strong data-start="5196" data-end="5208">CAN-2409</strong>
<ul data-start="5213" data-end="5295">
<li data-section-id="omxann" data-start="5213" data-end="5245">Company: Candel Therapeutics</li>
<li data-section-id="691xiq" data-start="5248" data-end="5269">RoA: Intratumoral</li>
<li data-section-id="rju5vo" data-start="5272" data-end="5295">MoA: Gene transferase</li>
</ul>
</li>
</ul>
<h2 data-section-id="1vhhkgj" data-start="5297" data-end="5313"><strong>Key Companies</strong></h2>
<ul data-start="5314" data-end="5562" data-is-last-node="" data-is-only-node="">
<li data-section-id="185uw5n" data-start="5314" data-end="5327">AstraZeneca</li>
<li data-section-id="111uwtp" data-start="5328" data-end="5350">Boehringer Ingelheim</li>
<li data-section-id="38th5m" data-start="5351" data-end="5359">Pfizer</li>
<li data-section-id="1ru33vm" data-start="5360" data-end="5384">Takeda Pharmaceuticals</li>
<li data-section-id="1o2uvpq" data-start="5385" data-end="5404">Johnson &amp; Johnson</li>
<li data-section-id="1rrr14k" data-start="5405" data-end="5416">Eli Lilly</li>
<li data-section-id="42h6c6" data-start="5417" data-end="5439">Bristol-Myers Squibb</li>
<li data-section-id="16vqgfu" data-start="5440" data-end="5447">Merck</li>
<li data-section-id="1w96t2r" data-start="5448" data-end="5456">AbbVie</li>
<li data-section-id="16yjn6w" data-start="5457" data-end="5464">Amgen</li>
<li data-section-id="1qvkx7p" data-start="5465" data-end="5486">Mirati Therapeutics</li>
<li data-section-id="p54y76" data-start="5487" data-end="5497">Novartis</li>
<li data-section-id="q3wkut" data-start="5498" data-end="5507">Immutep</li>
<li data-section-id="naa4c1" data-start="5508" data-end="5530">Moderna Therapeutics</li>
<li data-section-id="11jq1a2" data-start="5531" data-end="5544">ImmunityBio</li>
<li data-section-id="vysgz1" data-start="5545" data-end="5562" data-is-last-node="">Gilead Sciences</li>
</ul>
<p><strong>Stay updated with us for Recent Articles @ <a href="https://www.delveinsight.com/blog">New DelveInsight Blogs</a></strong></p>

Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC) Market

Non-Small Cell Lung Cancer Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.